Several studies have reported a significant role of high mobility group box protein 1 (HMGB1) in lung cancer. Nevertheless, there is a lack of knowledge regarding the expression of HMGB1 and its correlation with the clinicopathological features of lung cancer. In addition, the potential molecular mechanisms underlying the role of HMGB1 in lung cancer are still unknown. We therefore investigated the clinicopathological and prognostic significance as well as the potential role of HMGB1 in the development and progression of lung cancer. HMGB1 expression in the tumor tissues of the cohort correlated with clinicopathological features. Moreover, lung cell migration and invasion were significantly increased after treatment with HMGB1. The matrix metalloproteinase-2 (MMP-2) expression and activity were upregulated after treatment with HMGB1, while the upregulated expression of MMP-2 stimulated by HMGB1 in lung cancer cells was significantly reduced with the blockage of si-p65. These results indicated that HMGB1 expression was significantly associated with lung cancer progression. We also showed that HMGB1 promoted lung cancer invasion and metastasis by upregulating the expression and activity of MMP-2 in an NF-κB-dependent manner. Taken together, these data suggested that HMGB1 may be a potential prognosis and therapeutic marker for lung cancer.

1. Introduction

Lung cancer has currently become one of the most serious diseases threatening human health. Its incidence and mortality rates are the highest of all malignant tumors in the world [1–4]. Non-small cell lung cancer (NSCLC) accounts for 80%–85% of all lung cancers that involve a multifactorial, multistep, and multistage complex process [5–9]. Although significant progress has been made in clinical treatments with the rapid development of molecular biology techniques and clinical treatments, the survival of lung cancer patients is still limited. It is therefore important to investigate the molecular
mechanisms of invasion and metastasis of lung cancer and to identify potential prognostic markers.

High mobility group box protein 1 (HMGB1) is a non-histone, chromatin-binding nuclear protein that is widely found in eukaryotic cells, with a protein structure containing two homologous DNA-binding domains (A and B boxes) and a C-terminal tail that participates in transcription, DNA preparation, cell growth and differentiation, and extracellular signal transduction [10–12]. HMGB1 has been reported to be involved in cancer development, invasion, and metastases. In addition, HMGB1 is frequently highly expressed in various malignant tumors and is an early marker for these tumors [13–17]. In recent years, various studies to characterize the expression of HMGB1 in NSCLC patients have suggested that HMGB1 plays a vital role in the diagnosis and prognosis of NSCLC [12, 18–24]. However, this suggestion is still controversial. Shen et al. [22] suggested that HMGB1 is downregulated in NSCLC tissues, while other studies reported that the level of HMGB1 is upregulated in NSCLC tissues compared with that of normal tissues [12, 20, 24]. Thus, further research is needed to clarify the possible clinical diagnostic and prognostic values of HMGB1 in NSCLC.

It is well-known that invasion and metastasis, which are the main causes of high mortality, are common characteristics of malignant tumors. Extracellular HMGB1 is thought to induce cancer cell growth, mobility, invasion, and metastasis via binding to specific membrane receptors, including the receptor for advanced glycation end products (RAGE), and blockage of the RAGE-HMGB1 complex suppresses tumor growth and metastasis [20, 25–27]. Taguchi et al. also reported that the metastasis of Lewis lung tumor cells was inhibited when treated with anti-HMGB1 antibody, suggesting that HMGB1 is associated with tumor invasion and metastasis [26].

Matrix metalloproteinase 2 (MMP2) is a member of the Ca\(^{2+}\) and Zn\(^{2+}\)-dependent endogenous protease family (MMPs), whose expression in tumors is reported to be correlated with carcinoma invasion and metastasis [28–30]. MMP2 expression is upregulated in many cancers such as in glioblastomas, melanomas, breast cancers, and colon cancers [30]. It has also been reported that the high MMP2 expression in NSCLC is an independent prognostic factor that is closely related to its clinical stage, pathological grade, lymphatic metastasis, and prognosis [19].

As a key transcription factor, the nuclear factor (NF)-κB plays an important role in tumor development and progression [31]. Activated NF-κB can trigger chemokine and cytokine production, which further results in tissue damage [32]. Moreover, activated NF-κB signaling pathways have been correlated with MMP2 expression, and there is evidence that deacetylation of NF-κB reduces MMP2 expression, leading to the inhibition of NSCLC cell invasion [33].

However, the underlying mechanisms involving HMGB1 promotion of lung cancer invasion and metastasis still remain unclear and require further elucidation. In the present study, our aim was to characterize the association between the expression of HMGB1 and the clinicopathological and prognostic factors of NSCLC and to investigate how HMGB1 promotes lung cancer invasion and metastasis.

2. Materials and Methods

2.1. Materials. The lung cancer tissue chip was purchased from Shanghai core Biological Technology Co., Ltd., number HLug-Adel80Sur-01. In 90 cases of lung cancer tissues and 90 cases of lung adjacent noncancerous tissues, TNM stage was I–III stages; lymph node metastasis was N0 in 39 cases, N1–N3 in 36 cases, and N × 15 cases in other cases. The clinical data and follow-up data were complete. The operation time was 2004.7–2009.6; the follow-up time was 2014.8, followed up for 5–10 years.

A549 and H1299 cell lines were purchased from the US standard library (American Type Culture Collection, ATCC).

2.2. Immunohistochemical Staining. The immunohistochemical staining method we used was Envision™, performed as described previously [34]. As for tissue immunohistochemistry staining results analysis, lung cancer tissue staining results were evaluated by IRS score under double-blind conditions by two senior pathological experts. The average staining score was calculated by combining the positive staining intensity and the percentage of positive cells. Dyeing strength was as follows: nonstaining, 0 points; weak coloring, 1 points; medium coloring, 2 points; strong coloring, 3 points. The percentage of positive cells ranged from 0 to 25%, 1 points; 26% to 50%, 2 points; 51% to 75%, 3 points; 76% to 100%, 4 points. Two points multiplied by the following scores: 0 for negative; 1–3 for weak positive; 4–6 for medium positive; and 8–12 for strong positive. We stipulated 4 points and below for HMGB1 low expression and 4 points above for HMGB1 high expression.

2.3. In Vitro Invasion Assay. The in vitro invasion assays were carried out using Transwell® chamber with 6.5 mm diameter polycarbonate filters as described previously [35]. HMGB1 pretreated lung cancer cells digested by trypsin were suspended by serum-free medium and then counted. The concentrations of A549 and H1299 were 4.5 × 10\(^6\)/ml and 3 × 10\(^6\)/ml, respectively. 10% serum was added to the bottom of the 24-orifice plate and cell suspension was added to the incubation chamber for 24 hours. We made the methanol fixation at RT for 30 min and then the PBS wash twice. Crystal violet was dyed for 15–30 minutes and 5 pictures were taken at random under the microscope and counted.

2.4. Gelatin Zymography. Gelatin zymography was performed as described previously [36]. We collected the supernatant of HMGB1 pretreated or not lung cancer cells, measured the proteins concentration, and then mixed it with 4x loading buffer about 30–50 μg/40 ul. SDS-PAGE electrophoresis was performed at 100 V for about 1.5 hours. Low speed oscillation elution was carried out in 2.5% Triton X-100 eluted with SDS (elution for 90 minutes), followed by rinsing with distilled water and then gel incubation at 37°C for 60 h until a transparent strip appears. This was then stained at RT for 1–4 h and then destained for 2–5 h to observe the MMP2 strip.
Tissues Adjacent to the Lung Cancer.

3.1. Expression of HMGB1 in Lung Cancer Tissues and Normal Tissues Adjacent to Lung Cancers.

| Variables                       | HMGB1 staining |       |       | P*   |
|---------------------------------|----------------|-------|-------|------|
| Lung cancer tissues             | Low (43.3%)    | High (56.7%) | Total (90) | 0.001 |
| Adjacent noncancerous tissues   | 63 (70.0%)     | 27 (30.0%) | 90    |      |

*The Student t-test for P value.

2.5. Western Blot Analysis. Protein level was detected by western blot analysis as described previously [37]. After treatment with HMGB-1, A549 and H1299 cells were washed twice by ice-cold PBS. Cells were lysed by RIPA lysis buffer and then proteins were extracted. Denaturation of equal amount of supernatant protein in boiling SDS sample buffer was performed and then the samples were subjected to 10% SDS-PAGE. After that, polyvinylidene difluoride membranes were used for the proteins transfer. 5% dry skim milk was used for membrane blocking and then membranes were incubated with primary antibodies p65, MMP2. In this experiment, β-actin was used as an internal reference for the reliability of the experiment. Finally, membranes were treated with enhanced chemiluminescent system for visualization of the protein bands. The bands were quantified using Image J software.

2.6. Statistical Analysis. The correlation analysis of the expression level of HMGB1 and various clinicopathologic parameters was made using Fisher exact test. The survival data were analyzed using Kaplan–Meier survival curve analysis and Log-rank test. Measurement data represents mean ± standard deviation (x ± s). The means of two groups were compared with t test. We used SPSS18.0 statistical software for data processing. P < 0.05 shows that the difference was statistically significant, P < 0.01 shows that there is a significant difference.

3. Results

3.1. Expression of HMGB1 in Lung Cancer Tissues and Normal Tissues Adjacent to the Lung Cancer. Immunohistochemical staining showed that the HMGB1 high expression percentages in lung cancer tissues and normal tissues adjacent to the lung cancer tissues from 90 patients were 56.7% and 30.0%, respectively, which showed that the level of HMGB1 expression in lung cancer tissue was significantly higher than in the tissue adjacent to the lung cancers (Table 1).

3.2. The Relationship between the Expression of HMGB1 in Lung Cancer Tissue and Clinical Pathological Parameters. HMGB1 expression level was associated with the clinical pathological characteristics of the patients with lung cancer, such as T stage (P = 0.027) and lymph node metastasis of the tumor (P = 0.019), and was closely related to the clinical stage (P = 0.012). However, when compared with the patients’ gender, age, and size, there was no significant difference (P > 0.05) (Table 2).

3.3. The Relationship between the Level of HMGB1 Expression of Lung Cancer Tissue and the Prognoses of Patients. In order to investigate whether the high expression of HMGB1 was correlated with the poor prognosis of patients with lung cancers, we analyzed the 5-year survival rates of 90 cases of lung cancer patients using Kaplan–Meier survival curves. According to the staining intensity, we chose different time nodes using the survival analyses, which showed that the postoperative total survival percentage of high HMGB1 expression was significantly lower than low HMGB1 expression for lung cancer patients (P = 0.0011, HR = 0.0011, 95% CI: 0.2623 0.7166; Figure 1). Overall, the results showed that the high expression of HMGB1 was closely related to the poor prognoses of patients with lung cancer.

3.4. HMGB1 Promotes Lung Cancer Cell Invasion. In order to determine whether HMGB1 promoted lung cancer cell invasion, the lung cancer cell lines, A549 and H1299, were pretreated with HMGB1, and the Transwell assay was used to determine the changes of cell invasion. Compared with the control group, the number of A549 and H1299 cells passing through the Transwell chambers increased by 46% and 41%, respectively, after pretreatment with HMGB1. The increased invasiveness was significantly different, suggesting that treatment with HMGB1 increases the invasive ability of lung cancer cells (Figure 2).

3.5. HMGB1 Activates MMP2 Enzyme Activity. To further study the mechanism of HMGB1-promoting lung cancer cell invasion, gelatin zymography assays were performed in lung cancer cell lines, A549 and H1299, after pretreatment with HMGB1. The results showed that MMP2 enzyme activities in the A549 and H1299 cells were significantly higher after treatment with HMGB1 than the control group (Figure 3).

3.6. HMGB1 Promotes MMP-2 Expression via the NF-κB Pathway. Our previous study showed that HMGB1 induced NF-κB expression in human bronchial epithelial cells in a dose-dependent manner. To investigate the mechanism of HMGB1 promotion of MMP2 expression, western blots were used to detect NF-κB expression. The results showed...
Table 2: The relationship between high mobility group box protein 1 staining and the clinicopathological characteristics of 90 lung cancer patients.

| Variables     | Low (%) | High (%) | Total | P*   |
|---------------|---------|----------|-------|------|
| Age           |         |          |       |      |
| ≥60 years     | 23 (41.8) | 32 (58.2) | 55    | 0.828|
| <60 years     | 16 (45.7) | 19 (54.3) | 35    |       |
| Gender        |         |          |       |      |
| Male          | 19 (38.8) | 30 (61.2) | 49    | 0.396|
| Female        | 20 (48.8) | 21 (51.2) | 41    |       |
| Tumor size    |         |          |       |      |
| ≥4 cm         | 23 (44.2) | 28 (55.8) | 51    | 0.832|
| <4 cm         | 16 (41.0) | 23 (59.0) | 39    |       |
| pT status     |         |          |       |      |
| pT1-pT2       | 34 (50.7) | 33 (49.3) | 67    | 0.027|
| pT3-pT4       | 5 (21.7)  | 18 (78.3) | 23    |       |
| pN status     |         |          |       |      |
| pN0           | 22 (56.4) | 17 (43.6) | 39    | 0.019|
| pN1-pN3       | 10 (27.8) | 26 (72.2) | 36    |       |
| TNM stage     |         |          |       |      |
| I-II          | 35 (50.7) | 34 (49.3) | 69    | 0.012|
| III           | 4 (19.0)  | 17 (81.0) | 21    |       |

*The Student t-test for P value.

Figure 2: High mobility group box protein 1 (HMGB1) promoted invasion of lung cancer cells. Pretreatment of HMGB1 significantly promoted invasion of A549 and H1299 cells.

Figure 3: HMGB1 promoted the activity of MMP2 in lung cancer cells. Pretreatment of HMGB1 significantly promoted the activity of MMP2 in A549 and H1299 cells (**P < 0.01 compared with the control). Significant differences were assessed by the Student t-test.

Figure 4: HMGB1 promoted invasion of lung cancer cells. Pretreatment of HMGB1 significantly increased NF-κB expression of the HMGB1 pretreatment group versus the control group. In addition, p65 siRNA was transfected into the A549 and H1299 lung cancer cell lines, together with HMGB1 treatment. Compared with the control group, treatment with HMGB1 promoted MMP2 expression when there was no p65 siRNA transfection, while the expression of MMP2 was significantly decreased in the p65 siRNA transfection groups compared with the p65 siRNA control group (Figure 5). These results showed that HMGB1 increased the expression of MMP2, thus promoting the invasive ability of lung cancer cells via the NF-κB pathway.
4. Discussion

Little is known about the pathogenesis of NSCLC and the identification of effective markers for early diagnosis and prognosis of NSCLC. Therefore, identification of effective markers for early diagnosis and prognosis of NSCLC has become an important objective of recent studies. HMGB1 has been reported to be associated with the progression of NSCLC. Recent studies have shown that HMGB1 can participate in cell differentiation, migration, regeneration, and mediation of inflammation, particularly in binding to RAGE, to affect tumor growth, invasion, and metastasis [38]. Shang et al. first reported that serum HMGB1 levels were significantly increased in patients with lung cancer when compared with control subjects [20]. In the present study, we used tumor tissue microarrays to characterize an independent cohort of 90 NSCLC patients for the expression of HMGB1. The clinical analyses showed a significantly higher expression of HMGB1 in the lung cancer tissues than in the adjacent normal tissues. Furthermore, there was a correlation between HMGB1 expression with TNM staging and the postoperative survival of lung cancer patients, which was similar to the results of previous studies [17]. Taken together, the results suggested that HMGB1 plays an important role in tumor progression and may be useful in the prognoses of NSCLC patients.

It is well-known that tumor cell migration and invasion are major factors leading to cancer deterioration that affects the prognoses of patients. Many studies have reported that HMGB1 is associated with cancer cell migration and invasion.
prognoses of lung cancer patients, promoted lung cancer invasion and metastasis by upregulating the expression and activity of MMP-2 via an NF-κB-dependent pathway. These findings may assist in clinical diagnoses and suggest therapeutic strategies for patients with NSCLC.

Disclosure
Xiaojin Wu and Weitao Wang are co-first authors.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Acknowledgments
This study was supported by grants from the Foundation of Jiangsu Provincial Commission of Health and Family Planning (QMRRC2016363); Key Talents of Medical Science in Jiangsu Province (Z201627); Xuzhou Administration of Science & Technology (KC14SH009); the 333 high-level talents of Jiangsu Province ((2016)-1903).

References
[1] C. Zhang, S. Ge, C. Hu, N. Yang, and J. Zhang, “MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer,” Acta Biochimica et Biophysica Sinica, vol. 45, no. 12, pp. 1055–1061, 2004.
[2] X. Wu, Y. Mi, H. Yang, A. Hu, Q. Zhang, and C. Shang, “The activation of HMGBI as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway,” Molecular and Cellular Biochemistry, vol. 380, no. 1-2, pp. 249–257, 2013.
[3] W. W. B. Goh, M. Fan, H. S. Low, M. Sergot, and L. Wong, “Enhancing the utility of Proteomics Signature Profiling (PSP) with Pathway Derived Subnets (PDSs), performance analysis and specialised ontologies,” BMC Genomics, vol. 14, no. 1, article no. 35, 2013.
[4] P. Chunhacha and P. Chanvorachote, “Roles of caveolin-1 on anokia in resistance in non small cell lung cancer,” International Journal of Physiology, Pathophysiology and Pharmacology, vol. 4, no. 3, pp. 149–155, 2012.
[5] C. Hou, H. Zhao, W. Li, and S. Cai, “Hydrogen peroxide induces high mobility group box 1 release in human bronchial epithelial cells,” Journal of Southern Medical University, vol. 32, no. 8, pp. 1131–1134, 2012.
[6] X. Yang M and H. Yang, “Expression of high mobility group box-1 in the lung tissue and serum of patients with pulmonary tuberculosis,” Zhonghua jie he he hu xi zai zhi, vol. 36, no. 7, pp. 497–500, 2013.
[7] L. Conti, S. Lanzardo, M. Arigoni et al., “The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells,” The FASEB Journal, vol. 27, no. 12, pp. 4731–4744, 2013.
[8] D. Shrimali, M. K. Shanmugam, A. P. Kumar et al., “Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer,” Cancer Letters, vol. 341, no. 2, pp. 139–149, 2013.
[9] S.-Y. Chiou, Y.-S. Lee, M.-J. Jeng, P.-C. Tsao, and W.-J. Soong, “Moderate hypothermia attenuates oxidative stress injuries in alveolar epithelial A549 cells,” Experimental Lung Research, vol. 39, no. 6, pp. 217–228, 2013.
[10] J. E. Ellerman, C. K. Brown, M. de Vera et al., “Masquerader: high mobility group box-1 and cancer,” Clinical Cancer Research, vol. 13, no. 10, pp. 2836–2848, 2007.
[11] P.-L. Liu, J.-R. Tsai, J.-J. Hwang et al., “High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness,” American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 5, pp. 530–538, 2010.
[12] J.-L. Wang, D.-W. Wu, Z.-Z. Cheng, W.-Z. Han, S.-W. Xu, and N.-N. Sun, “Expression of High Mobility Group Box-B1 (HMGB-1) and Matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC),” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 12, pp. 4865–4869, 2014.
[13] D. Süren, M. Yildirim, O. Demirpence et al., “The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer,” Medical Science Monitor, vol. 20, pp. 530–537, 2014.
[14] Y. R. Choi, H. Kim, H. J. Kang et al., “Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation,” Cancer Research, vol. 63, no. 9, pp. 2188–2193, 2003.
[15] Q. Hao, X.-Q. Du, X. Fu, and J. Tian, “Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma,” Zhonghua Zhong Liu Za Zhi, vol. 30, no. 4, pp. 292–295, 2008.
[16] A. Feng, Z. Tu, and B. Yin, “The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer,” Oncotarget, vol. 7, pp. 20507–20519, 2016.
[17] K. Jakubowska, W. Naumnik, W. Niklińska, and E. Chyczewska, “Clinical significance of HMGB-1 and TGF-β level in serum and BALF of advanced non-small cell lung cancer,” Advances in Experimental Medicine and Biology, vol. 852, pp. 49–58, 2015.
[18] X. Zhang, H. Yang, and J. Wang, “Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer,” Wsypolczesna Onkologia, vol. 17, no. 4, pp. 350–355, 2013.
[19] G.-H. Shang, C.-Q. Jia, H. Tian et al., “Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer,” Respiratory Medicine, vol. 103, no. 12, pp. 1949–1953, 2009.
[20] W. Naumnik, W. Niklińska, M. Ossolińska, and E. Chyczewska, “Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy,” Folia Histochemica et Cytobiologica, vol. 47, no. 4, pp. 703–709, 2009.
[21] X. Shen, L. Hong, H. Sun, M. Shi, and Y. Song, “The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer,” Oncology Reports, vol. 22, no. 3, pp. 535–539, 2009.
[22] J.-K. Sun, C. Ji, X. Li et al., “Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells,” Molecular Medicine Reports, vol. 7, no. 5, pp. 1678–1682, 2013.
[23] Q. Xia, J. Xu, H. Chen et al., “Association between an elevated level of HMGB1 and non-small-cell lung cancer: A meta-analysis and literature review,” OncoTargets and Therapy, vol. 9, pp. 3917–3923, 2016.
[25] H. J. Huttunen, C. Fages, and H. Rauvala, “Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways,” The Journal of Biological Chemistry, vol. 274, no. 28, pp. 19919–19924, 1999.

[26] A. Taguchi, D. C. Blood, G. Del Toro et al., “Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000.

[27] J. S. Park, F. Gamboni-Robertson, Q. He et al., “High mobility group box 1 protein interacts with multiple Toll-like receptors,” American Journal of Physiology-Cell Physiology, vol. 290, no. 3, pp. C917–C924, 2006.

[28] B. Schmalfeldt, D. Prechtel, K. Härting et al., “Increased MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer,” Clinical Cancer Research, vol. 17, no. 12, pp. 4167–4176, 2011.

[29] T. Koshiba, R. Hosotani, M. Wada et al., “Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma,” Cancer, vol. 82, no. 4, pp. 642–650, 1998.

[30] K. M. Panth, T. Van Den Beucken, R. Biemans et al., “In vivo optical imaging of MMP2 immuno protein antibody: Tumor uptake is associated with MMP2 activity,” Scientific Reports, vol. 6, Article ID 22198, 2016.

[31] M. Karin, “Nuclear factor-κB in cancer development and progression,” Nature, vol. 441, no. 7092, pp. 431–436, 2006.

[32] J. Fucikova, P. Kralikova, A. Fialova et al., “Human tumor cells killed by anthracyclines induce a tumor-specific immune response,” Cancer Research, vol. 71, no. 14, pp. 4821–4833, 2011.

[33] C.-J. Yang, Y.-P. Liu, H.-Y. Dai et al., “Nuclear HDAC6 inhibits invasion by suppressing NF-kB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer,” Oncotarget, vol. 6, no. 30, pp. 30263–30276, 2015.

[34] E. Sabattini, K. Bisgaard, S. Ascani et al., “The EnVision(TM)+ system: A new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate(TM), CSA, LABC, and SABC techniques,” Journal of Clinical Pathology, vol. 51, no. 7, pp. 506–511, 1998.

[35] Y. M. Kim et al., “Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase,” Cancer Res, vol. 60, pp. 5410–5413, 2000.

[36] M. Toth, A. Sohail, and R. Fridman, “Assessment of Gelatinases (MMP-2 and MMP-9) by Gelatin Zymography,” in Metastasis Research Protocols, M. Dwek, S. A. Brooks, and U. Schumacher, Eds., vol. 788, pp. 121–135, Humana Press, 2012.

[37] Y. Zhang, J. Dong, P. He et al., “Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synovocytes of rheumatoid arthritis,” Inflammation, vol. 35, no. 1, pp. 377–387, 2012.

[38] L. L. Mantell, W. R. Parrish, and L. Ulloa, “HMGB-1 as a therapeutic target for infectious and inflammatory disorders,” Shock, vol. 25, no. 1, pp. 4–11, 2006.

[39] P. Xiao and W. L. Liu, “MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 9, pp. 10800–10807, 2015.

[40] T. Klein and R. Bischoff, “Physiology and pathophysiology of matrix metalloproteases,” Amino Acids, vol. 41, no. 2, pp. 271–290, 2011.